TOBY's Urine Test Gets FDA Fast-Track, Aims to Upend Cancer Screening

AUSTIN, Texas – April 14, 2026 – A simple urine test could soon become a powerful new weapon in the war on cancer. Biotechnology firm TOBY, Inc. announced today that its non-invasive, multi-cancer early detection (MCED) test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The designation signals federal recognition of the test's potential to significantly improve cancer diagnosis and accelerates its path toward clinical use, positioning it as a disruptive challenger in a market currently dominated by blood-based screening technologies.

The test aims to identify molecular patterns from over ten different cancers through a single urine sample, a method that promises unprecedented accessibility and ease of use for patients. This development could represent a pivotal moment in public health, potentially shifting the paradigm of cancer screening from targeted, often invasive procedures to routine, population-wide monitoring.

"This Breakthrough Device Designation marks a defining moment for TOBY and for the future of cancer screening," said Matthew Laskowski, Chief Executive Officer of TOBY, in a statement. He emphasized the company's belief that simple, accessible approaches are the future of cancer detection, enabling screening to happen "earlier and at scale."

A New Frontier in Cancer Detection

At the heart of TOBY's innovation is a technology that "sniffs out" cancer. The platform analyzes volatile organic compounds (VOCs)—tiny, odorous molecules excreted in urine—using advanced spectroscopy and machine learning. The underlying science, known as volatilomics, is based on the principle that cancerous tumors have a unique metabolic fingerprint, releasing specific VOCs that can act as biomarkers. By training its algorithms to recognize these cancer-associated patterns, the test can flag the potential presence of disease long before symptoms appear.

This approach stands in stark contrast to the prevailing methods in the burgeoning MCED market. Industry giants like Grail, a subsidiary of Illumina, and Exact Sciences have invested billions in "liquid biopsies" that analyze cell-free DNA (cfDNA) circulating in the bloodstream for genetic or epigenetic signs of cancer. While these blood tests, such as Grail's Galleri, have shown significant promise in detecting dozens of cancer types, they still require a phlebotomist to draw blood.

TOBY's urine-based method bypasses the needle entirely. The simplicity of collecting a urine sample could dramatically lower barriers to screening, potentially boosting patient compliance and making large-scale screening programs more logistically and financially feasible. This is particularly crucial for reaching underserved communities or individuals with a fear of needles. The platform builds on TOBY's previous success, which includes an earlier FDA Breakthrough Device Designation for a urine test specifically designed to detect bladder cancer, suggesting a strong foundational technology.

"A single, non-invasive urine sample that aims to deliver on the necessary early stage accuracy, improved affordability and broadly available accessibility to enable screening for many cancers is exactly that kind of platform," stated Matthew Collier, Chief Executive Officer of TOBY Oncology.

The Strategic Power of 'Breakthrough' Status

Receiving the FDA's Breakthrough Device Designation is a significant milestone, but it is not a market approval. Instead, the program is designed to act as an accelerator for technologies that could provide more effective diagnosis for life-threatening diseases. It grants TOBY a prioritized review process and, critically, a more collaborative and frequent dialogue with FDA experts. This enhanced communication can help streamline the complex process of designing clinical trials and navigating regulatory requirements, potentially shaving months or even years off the typical development timeline.

This designation serves as a powerful validation of the technology's potential. The FDA reserves this status for innovations it believes can offer substantial improvements over existing options, not just incremental ones. For a relatively young company like TOBY, founded in 2023, this federal stamp of approval provides immense credibility. It acts as a strong, positive signal to investors, healthcare systems, and future commercial partners that the underlying science is sound and addresses a major unmet medical need.

Furthermore, this is the first time a urine-based MCED technology has received this designation, carving out a unique regulatory and market niche for the company. It distinguishes TOBY's platform from the crowded field of blood-based competitors and validates its novel approach in the eyes of the nation's primary medical regulatory body.

Navigating a Competitive and Cautious Market

While the FDA designation provides a significant tailwind, TOBY is entering a fiercely competitive arena. The quest for a reliable multi-cancer screening test has been called the "holy grail" of diagnostics, attracting massive investment and intense research activity. Companies like Grail, Guardant Health, and Exact Sciences are already well-established, with their blood-based tests in various stages of clinical use and development.

TOBY's primary advantage is its non-invasive nature. However, it also faces the challenge of proving its scientific rigor against more established methods. The science of urine volatilomics for multi-cancer detection is less mature than the analysis of circulating tumor DNA in blood. Experts in the field, while excited by the potential, remain cautiously optimistic.

"The concept is incredibly appealing. A simple, take-home test could revolutionize screening compliance," commented one oncologist not affiliated with the company. "But the burden of proof is immense. Urine is a complex biological sample, and its composition can be affected by everything from diet to medication. The company will need to demonstrate in large, diverse clinical trials that its test can reliably distinguish cancer signals from all that background noise with very high accuracy."

The key challenge will be to achieve both high sensitivity (correctly identifying those with cancer) and high specificity (correctly identifying those without cancer). A high rate of false positives could lead to "overdiagnosis," subjecting healthy individuals to unnecessary anxiety and follow-up invasive procedures, while a low sensitivity would miss cancers, defeating the purpose of the test.

The Road Ahead: From Designation to Clinical Reality

The Breakthrough Designation is the starting gun, not the finish line. TOBY's immediate future will be dominated by the need to generate robust clinical evidence. The company has stated the designation will help accelerate its expanded clinical studies, which will be essential for securing eventual FDA marketing authorization. These trials must prove that the test not only detects cancer accurately but also demonstrates clear clinical utility—that is, that its use leads to better patient outcomes, such as catching cancers at an earlier, more treatable stage and ultimately saving lives.

Beyond regulatory approval, the company faces the hurdles of reimbursement and clinical adoption. To become a routine part of care, the test must be covered by insurers like Medicare and private payers. This will require a strong health-economic argument demonstrating that the cost of screening is justified by the savings from treating cancers earlier and the value of lives saved.

Finally, TOBY will need to win the trust of clinicians. Doctors will require clear, evidence-based guidelines on how to interpret the test's results, which cancers it is most effective at detecting, and what the appropriate next steps are for a positive result. Integrating a novel screening tool into established medical practice is a slow and deliberate process. However, if TOBY can successfully navigate this challenging path, its vision of making early, accessible cancer detection a routine reality could profoundly reshape modern medicine.